Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
December 2017, Vol 8, No 5
December 2017, Vol 8, No 5
Uncertainty Clouds the Affordable Care Act: Cost-Sharing Subsidies, CHIP on the Block
By
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Ongoing uncertainty over cost-sharing reduction payments and premium subsidies threatens the sustainability of the Affordable Care Act (ACA) and the implementation of various quality initiatives contained within it. Consequently, several health plans are reducing their footprint in the health insurance exchanges, further threatening the stability of the ACA.
Read Article
New Therapeutic Agents for the Treatment of B-Cell Acute Lymphocytic Leukemia
By
Corbin Davis
NCCN Hematologic Malignancies News
December 2017, Vol 8, No 5
San Francisco, CA—Therapies targeting immune responses against solid tumors have led to dramatic improvements in outcomes, but the role for immunotherapy in the treatment of acute leukemia is still being defined.
Read Article
2017 the Year of Acute Myeloid Leukemia: New Targeted Therapies
By
Corbin Davis
NCCN Hematologic Malignancies News
December 2017, Vol 8, No 5
San Francisco, CA—After nearly 40 years of negligible drug development, in 2017 the FDA approved 4 drugs for acute myeloid leukemia (AML). These novel therapies have been shown to decrease relapse rates, improve response rates in patients with specific mutations, and reduce short- and long-term adverse reactions associated with current treatment strategies.
Read Article
Nivolumab Active in HPV-Positive Gynecologic Cancers
By
Charles Bankhead
Gynecologic Cancer
December 2017, Vol 8, No 5
Chicago, IL—Treatment with nivolumab (Opdivo) led to durable responses and stable disease in a majority of women with relapsed or metastatic cancers caused by human papillomavirus (HPV) infection, according to the results of a phase 1/2 clinical trial—CheckMate-358.
Read Article
Treating Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
NCCN Hematologic Malignancies News
,
Hematologic Malignancies
December 2017, Vol 8, No 5
San Francisco, CA—Recent advances in the treatment of patients with multiple myeloma have dramatically altered the trajectory of the disease, as providers now have several efficacious agents in various drug classes at their disposal. At the 2017 NCCN Hematologic Malignancies Congress, Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN, provided management strategies for newly diagnosed multiple myeloma, including the role of autologous stem-cell transplant (ASCT) and posttransplant maintenance therapy.
Read Article
Online First
Alecensa a New First-Line Treatment for NSCLC with ALK Mutation
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
November 6, 2017
, the FDA approved alectinib (Alecensa; Genentech) for the treatment of patients with
ALK
mutation–positive, metastatic non–small-cell lung cancer (NSCLC), as detected by an FDA-approved test. On the same day, the FDA also converted alectinib’s initial accelerated approval to a full approval for the treatment of patients with metastatic NSCLC and
ALK
mutation whose disease progressed with or who were intolerant of crizotinib (Xalkori).
Read Article
Online First
Calquence New Treatment Approved for Mantle-Cell Lymphoma
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
October 31, 2017
, the FDA granted accelerated approval to acalabrutinib (Calquence; AstraZeneca) for the treatment of adults with mantle-cell lymphoma (MCL) who have received at least 1 previous therapy. The FDA granted acalabrutinib priority review and breakthrough therapy and orphan drug designations for this indication.
Read Article
Online First
Verzenio a New CDK4/CDK6 Inhibitor Approved for Metastatic Breast Cancer
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
September 28, 2017
, the FDA approved abemaciclib (Verzenio; Eli Lilly), a cyclin-dependent kinase (CDK)4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, and as monotherapy for HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy and previous chemotherapy in the metastatic setting.
Read Article
Online First
Yescarta Second Gene Therapy Approved by FDA and First CAR T-Cell Therapy for Large B-Cell Lymphoma
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
October 18, 2017
, the FDA approved axicabtagene ciloleucel (Yescarta; Kite Pharma), a CD19-directed genetically modified CAR T-cell immunotherapy, for the treatment, after ≥2 lines of systemic therapies, of adults with several types of relapsed or refractory large B-cell lymphoma, including (1) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, (2) primary mediastinal large B-cell lymphoma, (3) high-grade B-cell lymphoma, and (4) DLBCL arising from follicular lymphoma.
Read Article
Online First
Aliqopa the Newest Treatment Approved for Adults with Relapsed Follicular Lymphoma
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On
September 14, 2017
, the FDA granted accelerated approval to copanlisib (Aliqopa; Bayer Healthcare) for the treatment of adults with relapsed follicular lymphoma who have received ≥2 previous systemic therapies. Copanlisib received priority review and an orphan drug designation for this indication.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
2.
AI and ML Decision Support Models
3.
Crystal S. Denlinger, MD, FACP, Named New CEO of NCCN
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION